Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention

Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pat...

Full description

Saved in:
Bibliographic Details
Published in:Oncology reviews 2016-12, Vol.10 (2), p.320-320
Main Authors: Mohammed, Amrallah A, El-Tanni, Hani, El-Khatib, Hani M, Mirza, Ahmad A, Mirza, Abdulrahim A, Alturaifi, Turki H
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Bladder cancer
Cancer therapies
Cell cycle
Genes
Growth factors
Kinases
Labeling
Medical prognosis
Metastasis
Mortality
Multivariate analysis
Mutation
Pharmacodynamics
Proteins
Review
targeted therapies
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3293-83fcf64a7feea6db831987d21b2787dbf9c6e4812892d21142fae6a53a16880b3
cites
container_end_page 320
container_issue 2
container_start_page 320
container_title Oncology reviews
container_volume 10
creator Mohammed, Amrallah A
El-Tanni, Hani
El-Khatib, Hani M
Mirza, Ahmad A
Mirza, Abdulrahim A
Alturaifi, Turki H
description Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparison with other more common malignancies. This topic will discuss the molecular pathways, biomarkers and potential targets that may improve the outcome in BCa.
doi_str_mv 10.4081/oncol.2016.320
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aefd211961284b2689d84756aa542bb4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aefd211961284b2689d84756aa542bb4</doaj_id><sourcerecordid>1856589959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3293-83fcf64a7feea6db831987d21b2787dbf9c6e4812892d21142fae6a53a16880b3</originalsourceid><addsrcrecordid>eNqFks1vEzEQxVcIREvhyhFZ4sKBpP5emwNSGxWoVEBI6dma3Z1NN2zW6XgDyn-P04Sq5cJprPF7P834uSheCz7V3InTONSxn0ou7FRJ_qQ4Fr7kE2OsefrgfFS8SGnJecm5Mc-LI-m4cdy74-LHNXUD0Jad99A0SGwGQ430gZ13cQX0EykxGBo2B1rgyOY3SLDevmff8De7IGBtJPY1ErKzccRh7OLwsnjWQp_w1aGeFNefLuazL5Or758vZ2dXk1pJryZOtXVrNZQtItimckp4VzZSVLLMtWp9bVE7IZ2XuSu0bAEtGAXCOscrdVJc7rlNhGVYU5fH3YYIXbhrRFoEoLGrewyA7Q7hbabpSlrnG6dLYwGMllWlM-vjnrXeVCts6rwJQf8I-vhm6G7CIv4KRpTOaZUBpwcALHBNmNK9WfCwSyrcJRV2SYWcVHa8Ozgo3m4wjWHVpRr7HgaMmxSEy7k5743P0rf_SJdxQ0N-3CCtlGXpudqppntVTTElwvb_E7x5uPS9_O_nUH8Aty24qA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622779039</pqid></control><display><type>article</type><title>Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Mohammed, Amrallah A ; El-Tanni, Hani ; El-Khatib, Hani M ; Mirza, Ahmad A ; Mirza, Abdulrahim A ; Alturaifi, Turki H</creator><creatorcontrib>Mohammed, Amrallah A ; El-Tanni, Hani ; El-Khatib, Hani M ; Mirza, Ahmad A ; Mirza, Abdulrahim A ; Alturaifi, Turki H</creatorcontrib><description>Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparison with other more common malignancies. This topic will discuss the molecular pathways, biomarkers and potential targets that may improve the outcome in BCa.</description><identifier>ISSN: 1970-5565</identifier><identifier>ISSN: 1970-5557</identifier><identifier>EISSN: 1970-5565</identifier><identifier>EISSN: 1970-5557</identifier><identifier>DOI: 10.4081/oncol.2016.320</identifier><identifier>PMID: 28058098</identifier><language>eng</language><publisher>Switzerland: PAGEPress Publications</publisher><subject>Apoptosis ; Biomarkers ; Bladder cancer ; Cancer therapies ; Cell cycle ; Genes ; Growth factors ; Kinases ; Labeling ; Medical prognosis ; Metastasis ; Mortality ; Multivariate analysis ; Mutation ; Pharmacodynamics ; Proteins ; Review ; targeted therapies ; Tumors</subject><ispartof>Oncology reviews, 2016-12, Vol.10 (2), p.320-320</ispartof><rights>2016. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright A.A. Mohammed et al. 2016 Licensee PAGEPress, Italy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3293-83fcf64a7feea6db831987d21b2787dbf9c6e4812892d21142fae6a53a16880b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2622779039/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2622779039?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,25753,27922,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28058098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohammed, Amrallah A</creatorcontrib><creatorcontrib>El-Tanni, Hani</creatorcontrib><creatorcontrib>El-Khatib, Hani M</creatorcontrib><creatorcontrib>Mirza, Ahmad A</creatorcontrib><creatorcontrib>Mirza, Abdulrahim A</creatorcontrib><creatorcontrib>Alturaifi, Turki H</creatorcontrib><title>Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention</title><title>Oncology reviews</title><addtitle>Oncol Rev</addtitle><description>Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparison with other more common malignancies. This topic will discuss the molecular pathways, biomarkers and potential targets that may improve the outcome in BCa.</description><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Bladder cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Genes</subject><subject>Growth factors</subject><subject>Kinases</subject><subject>Labeling</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Mutation</subject><subject>Pharmacodynamics</subject><subject>Proteins</subject><subject>Review</subject><subject>targeted therapies</subject><subject>Tumors</subject><issn>1970-5565</issn><issn>1970-5557</issn><issn>1970-5565</issn><issn>1970-5557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFks1vEzEQxVcIREvhyhFZ4sKBpP5emwNSGxWoVEBI6dma3Z1NN2zW6XgDyn-P04Sq5cJprPF7P834uSheCz7V3InTONSxn0ou7FRJ_qQ4Fr7kE2OsefrgfFS8SGnJecm5Mc-LI-m4cdy74-LHNXUD0Jad99A0SGwGQ430gZ13cQX0EykxGBo2B1rgyOY3SLDevmff8De7IGBtJPY1ErKzccRh7OLwsnjWQp_w1aGeFNefLuazL5Or758vZ2dXk1pJryZOtXVrNZQtItimckp4VzZSVLLMtWp9bVE7IZ2XuSu0bAEtGAXCOscrdVJc7rlNhGVYU5fH3YYIXbhrRFoEoLGrewyA7Q7hbabpSlrnG6dLYwGMllWlM-vjnrXeVCts6rwJQf8I-vhm6G7CIv4KRpTOaZUBpwcALHBNmNK9WfCwSyrcJRV2SYWcVHa8Ozgo3m4wjWHVpRr7HgaMmxSEy7k5743P0rf_SJdxQ0N-3CCtlGXpudqppntVTTElwvb_E7x5uPS9_O_nUH8Aty24qA</recordid><startdate>20161214</startdate><enddate>20161214</enddate><creator>Mohammed, Amrallah A</creator><creator>El-Tanni, Hani</creator><creator>El-Khatib, Hani M</creator><creator>Mirza, Ahmad A</creator><creator>Mirza, Abdulrahim A</creator><creator>Alturaifi, Turki H</creator><general>PAGEPress Publications</general><general>PAGEPress Scientific Publications, Pavia, Italy</general><general>PAGEPress Publications, Pavia, Italy</general><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>67V</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20161214</creationdate><title>Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention</title><author>Mohammed, Amrallah A ; El-Tanni, Hani ; El-Khatib, Hani M ; Mirza, Ahmad A ; Mirza, Abdulrahim A ; Alturaifi, Turki H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3293-83fcf64a7feea6db831987d21b2787dbf9c6e4812892d21142fae6a53a16880b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Bladder cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Genes</topic><topic>Growth factors</topic><topic>Kinases</topic><topic>Labeling</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Mutation</topic><topic>Pharmacodynamics</topic><topic>Proteins</topic><topic>Review</topic><topic>targeted therapies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohammed, Amrallah A</creatorcontrib><creatorcontrib>El-Tanni, Hani</creatorcontrib><creatorcontrib>El-Khatib, Hani M</creatorcontrib><creatorcontrib>Mirza, Ahmad A</creatorcontrib><creatorcontrib>Mirza, Abdulrahim A</creatorcontrib><creatorcontrib>Alturaifi, Turki H</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Pagepress</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oncology reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohammed, Amrallah A</au><au>El-Tanni, Hani</au><au>El-Khatib, Hani M</au><au>Mirza, Ahmad A</au><au>Mirza, Abdulrahim A</au><au>Alturaifi, Turki H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention</atitle><jtitle>Oncology reviews</jtitle><addtitle>Oncol Rev</addtitle><date>2016-12-14</date><risdate>2016</risdate><volume>10</volume><issue>2</issue><spage>320</spage><epage>320</epage><pages>320-320</pages><issn>1970-5565</issn><issn>1970-5557</issn><eissn>1970-5565</eissn><eissn>1970-5557</eissn><abstract>Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparison with other more common malignancies. This topic will discuss the molecular pathways, biomarkers and potential targets that may improve the outcome in BCa.</abstract><cop>Switzerland</cop><pub>PAGEPress Publications</pub><pmid>28058098</pmid><doi>10.4081/oncol.2016.320</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1970-5565
ispartof Oncology reviews, 2016-12, Vol.10 (2), p.320-320
issn 1970-5565
1970-5557
1970-5565
1970-5557
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_aefd211961284b2689d84756aa542bb4
source Publicly Available Content (ProQuest); PubMed Central
subjects Apoptosis
Biomarkers
Bladder cancer
Cancer therapies
Cell cycle
Genes
Growth factors
Kinases
Labeling
Medical prognosis
Metastasis
Mortality
Multivariate analysis
Mutation
Pharmacodynamics
Proteins
Review
targeted therapies
Tumors
title Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A21%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20Bladder%20Cancer:%20Biomarkers%20and%20Target%20Therapy,%20New%20Era%20for%20More%20Attention&rft.jtitle=Oncology%20reviews&rft.au=Mohammed,%20Amrallah%20A&rft.date=2016-12-14&rft.volume=10&rft.issue=2&rft.spage=320&rft.epage=320&rft.pages=320-320&rft.issn=1970-5565&rft.eissn=1970-5565&rft_id=info:doi/10.4081/oncol.2016.320&rft_dat=%3Cproquest_doaj_%3E1856589959%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3293-83fcf64a7feea6db831987d21b2787dbf9c6e4812892d21142fae6a53a16880b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2622779039&rft_id=info:pmid/28058098&rfr_iscdi=true